Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Total Liabilities (2024 - 2025)

Pelthos Therapeutics has reported Total Liabilities over the past 2 years, most recently at $91.5 million for Q4 2025.

  • Quarterly results put Total Liabilities at $91.5 million for Q4 2025, up 2141.39% from a year ago — trailing twelve months through Dec 2025 was $91.5 million (up 2141.39% YoY), and the annual figure for FY2025 was $91.5 million, up 2141.39%.
  • Total Liabilities for Q4 2025 was $91.5 million at Pelthos Therapeutics, up from $68.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for PTHS hit a ceiling of $91.5 million in Q4 2025 and a floor of $2.8 million in Q2 2024.